<DOC>
	<DOCNO>NCT02625337</DOCNO>
	<brief_summary>This Phase 2 trial consist 24 patient receive combination dabrafenib + trametinib + pembrolizumab 3 different dose scheme 8 patient receive pembrolizumab standard monotherapy . All patient start pembrolizumab standard therapy 6 week randomize continue pembrolizumab monotherapy receive additional intermitted/short-term dabrafenib + trametinib . Stratification baseline LDH level baseline PD-L1 expression .</brief_summary>
	<brief_title>Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Adults least 18 year age World Health Organization ( WHO ) Performance Status 02 Histologically/cytologically confirm stage IV BRAF V600E K metastatic melanoma Measurable disease accord RECIST 1.1 At least one easy accessible lesion ( s.c. , lymph node ) repeatedly biopsied Patient willing undergo triple tumor biopsy screen , week 6 , week 8 ( cohort 24 ) , week 12 , week 18 , case disease progression . No prior immunotherapy target PD1 PDL1 ( CTLA4 target therapy allow ) No prior BRAF and/or MEK target therapy No immunosuppressive medication Screening laboratory value must meet following criterion : WBC ≥ 2.0x109/L , Neutrophils ≥ 1.0x109/L , Platelets ≥ 100 x109/L , Hemoglobin ≥ 5.0 mmol/L Creatinine ≤ 2x ULN AST , ALT ≤ 2.5 x ULN ( ≤5 x ULN patient liver metastasis ) Bilirubin ≤2 X ULN Female subject childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . Women child bear potential must agree use reliable form contraceptive study treatment period least 120 day follow last dose study drug Men must agree use male contraception study Treatment Period least 180 day last dose study drug . A potential subject meet follow criterion exclude study : Is currently participate participate study investigational agent use investigational device within 4 week first dose treatment . Presence symptomatic brain leptomeningeal metastasis ; patient asymptomatic brain metastasis detect screen study allow participate study Prior PD1/PDL1 target immunotherapy Has active automimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Subjects vitiligo resolve childhood asthma/atopy would exception rule . Subjects require intermittent use bronchodilator local steroid injection would exclude study . Subjects hypothyroidism stable hormone replacement Sjorgen 's syndrome exclude study . Has prior monoclonal antibody within 4 week prior study day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . Note : If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . Has evidence interstitial lung disease active , noninfectious pneumonitis . Known history Human Immunodeficiency Virus ; Active infection require therapy , positive test Hepatitis B surface antigen Hepatitis C ribonucleic acid ( RNA ) ; Has active tuberculosis Has receive live vaccine within 30 day prior first dose trial treatment . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . Patients another malignancy , free tumor 2 year allow inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>